TCT 25 - Dr Raj Makkar (Cedars-Sinai Medical Center, US) joins us to discuss the findings on the EVOQUE Valve (Edwards Lifesciences) drawing from data in the STS/ACC Transcatheter Valve Therapy Registry.

The study evaluated procedural success rates, in-hospital complications, and 30-day clinical outcomes in patients undergoing transcatheter tricuspid valve replacement for severe tricuspid regurgitation. Investigators compared observed outcomes against those reported in pivotal trials to assess real-world performance as the technology transitions from controlled study environments to broader clinical practice.

Real world findings with the EVOQUE system at 30 days demonstrated low mortality and heart failure hospitalisation rates, 97% of patients achieving ≤ mild tricuspid regurgitation, significant improvements in functional capacity and quality of life and reduced pacemaker and bleeding rates compared to randomized trials. Almost all patients were discharged home with a median 2-day hospital stay.

Interview Questions:

1. What is the background to this study and what is the STS/ACC TVT registry?
2. What was the study device?
3. What was the study design?
4. What is the patient population?
5. What are the key data presented at TCT 25?
6. What is the take-home message?

For more content from TCT 2025 head to the Late-breaking Science Video Collection.

Recorded remotely from San Francisco, 2025.
Editor: Mirjam Boros & Jordan Rance
Video Specialist: Tom Green & Mike Knight

Support: This is an independent interview produced by Transcatheter Academy.